Similarly, another study reported that anti-CTLA-4 mAB in combination with PI3Kα inhibitor provided synergistic antitumor activity, regressed breast tumors by 60%, and sensitized the tumor to ICI compared to ICI alone (Fig. 2) [119]. This evidence concerns the gene CTLA4 and neoplasm.